Clinical benefit from combination limb infusion and CTLA-4 blockade.

Slides:

Advertisements

Similar presentations

The Promise of Immunotherapy for Cancer Treatment

Advertisements

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Discussion Outline Cells of the Immune System.

Targeted therapy in melanoma

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Palumbo A et al. Proc ASCO 2011;Abstract 8007.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Targeting T Cell Co-receptors for Cancer Therapy

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Clinical responses in patients.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Percentage of patients per stage of oesophageal cancers in the two trials, overall difference P

George Blumenschein, MD, John V. Heymach, MD, PhD

Consort diagram i-scan multicentre trial NCT (clinicaltrials

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Forest plots for randomised and cluster randomised controlled trials from Cochrane review Biomarkers as point-of-care tests to guide prescription of antibiotics.

Trial design. Study design schematic of the PF-ILD trial followed by a separate open-label trial (optional): part A (visits 1 through 9 over 52 weeks)

Overall Survival and Progression-free Survival

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

The Development of an International Registry

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

coTCRcys-transduced T cells control tumor growth in vivo.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Development of 28 public molecular laboratories in France for molecular testing. Development of 28 public molecular laboratories in France for molecular.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Immunohistochemical detection of nuclear and cytoplasmic YB-1 in osteosarcoma and synovial sarcoma. Immunohistochemical detection of nuclear and cytoplasmic.

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

EN1 expression in breast cancer and clinical outcome.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

MDC/CCL22 and MMP-2 factors are found in the melanoma microenvironment and correlate with pDC accumulation and early relapse. MDC/CCL22 and MMP-2 factors.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Influence of ASGR2 expression on survival.

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Monocytes from melanoma patients are unresponsive to TLR3 agonists.

Comparative effect of anti-TIM3 against experimental tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Impact of IFNγ in B16 melanoma metastasis.

Schedule-dependent impact of costimulated activated T-cell transfer on T-cell reconstitution after tandem stem cell transplant. Schedule-dependent impact.

Immune profiling of patient-derived organotypic tumor spheroids.

Nanostring analysis of tumors after ILI and after combination limb infusion and ipilimumab. Nanostring analysis of tumors after ILI and after combination.

Progression and survival analysis.

Biopsies of the vaccination site were obtained 48 h after the first vaccination. Biopsies of the vaccination site were obtained 48 h after the first vaccination.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

Frequency and number of KLL-specific clonotypes in tumors from patients with KLL-specific T cells in PBMCs or cultured TILs. A wedge (the length of which.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

Immunohistochemical determination of TIM-3 expression in ccRCC.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

Clinical benefit from combination limb infusion and CTLA-4 blockade. Clinical benefit from combination limb infusion and CTLA-4 blockade. A, Schema of the phase II clinical trial. B, Swimmer plot of all patients, showing responses in the melphalan-treated limb. C, PFS for patients, including the 2 patients who died prior to the evaluation point. D, Example of durable response both in and outside of the limb of the infusion. This patient had an unknown primary melanoma and presented with multiple subcutaneous nodules of the limb, with groin adenopathy, biopsy-proven lung metastasis, and thoracic adenopathy. Three years after limb infusion and systemic ipilimumab, the patient remains free of disease (bottom plot). Charlotte E. Ariyan et al. Cancer Immunol Res 2018;6:189-200 ©2018 by American Association for Cancer Research